Home   Distributors   Careers   Contact


DESyne X2

• Eliminates the need for a primer coating
• Achieves a bare metal surface within 6–9 months
• Superior efficacy and excellent clinical safety


Desyne BD | Novolimus Eluting Coronary Stent System

BRS Not Created Equal



• State-of-the-art NOVOLIMUS™ eluting scaffold system
• Next generation in scaffold technology

learn more

Desolve | Novolimus Eluting Bioresorbable Coronary Scaffold System

• Improved performance
• Superior clinical efficacy and safety

learn more

The State of the Art Drug Eluting Stent

Unique Drug Agent Novolimus

Advanced Drug Coating/Polymer Technology
• Lowest polymer coating load2
• Reduced risk of adverse clinical events3
• Reliable performance with lower drug dose

Unique Drug Agent Novolimus

• Proprietary drug facilitates superior clinical efficacy5
• Established safety and performance
• Clinically proven 'olimus' drug family

About Elixir

Innovating Vascular Restoration™

Leading the Way to Next Generation DES Platforms

Elixir Medical Corporation, a privately held company headquartered in Milpitas, CA, specializes in developing products that combine state-of-the-art technology with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. Learn More...


In the News

Elixir Medical at EuroPCR 2019

The New Frontier Beyond Stenting for PCI

DynamX is not available for sale. 1Data based on pre-clinical studies.



Introducing DynamX™ – Metallic DES With Adaptive Remodeling

Professor Verheye Presents DESolve at PCR 2017

View PCR 2017 Presentation Slides

Professor Verheye

View the Presentation on PCR Online

Elixir shows resolve | BioWorld Medtech | Vol 21, Issue 200

Click here to view the full article